Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?

By Chris Lange Updated Jan 12, 12:16PM EST · Published May 6, 9:10AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? — © Thinkstock

[cnxvideo id=”625498″ placement=”ros”]Shares of Immunomedics Inc. (NASDAQ: IMMU) saw a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics Inc. (NASDAQ: SGEN). It may seem counterintuitive that shares would rise after such an announcement. So 24/7 Wall St. has taken a closer look at the report to see if this rise is justified.

Seattle Genetics decided to terminate the licensing deal following intense legal battles, also after Immunomedics announced that its president and CEO, Cynthia Sullivan, was no longer at the helm.

Back in February, Immunomedics inked a deal with Seattle Genetics for a potential $2 billion for the development of its IMMU-132, with a $250 million upfront payment, for the treatment of metastatic triple-negative breast cancer (mTNBC). However the deal was placed on Hold in March following a shareholder revolt.

Not to mention, that Seattle Genetics also will continue to hold roughly 3 million shares of Immunomedics common stock, as well as a warrant to purchase an additional 8.7 million shares at $4.90 per share.

[nativounit]

Immunomedics also will delay its submission for its Biologics License Agreement (BLA) for IMMU-132 until late in the fourth quarter of this year or in the first quarter of 2018.

Separately, the firm also made a $125 million private placement offer to further support the development of IMMu-132 to file a BLA for accelerated approval with the U.S. Food and Drug Administration (FDA). Currently the company only has a market cap of roughly $675 million.

Most of the rally in the shares was following the announcement of executives stepping down. It seems that this may have been more of a concern for investors than the deal being cut.

The mid-April short interest report noted that Immunomedics had 25.46 million shares short, compared to the previous level of 26.65 million.

Shares of Immunomedics closed Friday up 17.6% at $6.36, with a consensus analyst price target of $7.50 and a 52-week trading range of $1.95 to $7.15.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.